These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17302778)

  • 1. Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D.
    Nielsen LK; Green TH; Norderhaug L; Sandlie I; Dziegiel MH
    Transfusion; 2007 Feb; 47(2):306-15. PubMed ID: 17302778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn.
    Nielsen LK; Green TH; Sandlie I; Michaelsen TE; Dziegiel MH
    Transfusion; 2008 Jan; 48(1):12-9. PubMed ID: 17764508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells.
    Nielsen LK; Norderhaug L; Sandlie I; Dziegiel MH
    APMIS; 2006 May; 114(5):345-51. PubMed ID: 16725010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between the activities of human monoclonal IgG1 and IgG3 anti-D antibodies of the Rh blood group system in their abilities to mediate effector functions of monocytes.
    Wiener E; Jolliffe VM; Scott HC; Kumpel BM; Thompson KM; Melamed MD; Hughes-Jones NC
    Immunology; 1988 Oct; 65(2):159-63. PubMed ID: 3192267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG subclass distribution of anti-Rh, anti-Kell and anti-Duffy antibodies measured by sensitive haemagglutination assays.
    Michaelsen TE; Kornstad L
    Clin Exp Immunol; 1987 Mar; 67(3):637-45. PubMed ID: 3111763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of blending IgG1 and IgG3 monoclonal anti-D in promoting the metabolic response of monocytes to sensitized red cells.
    Hadley AG; Kumpel BM
    Immunology; 1989 Aug; 67(4):550-2. PubMed ID: 2504663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents.
    Montano RF; Penichet ML; Blackall DP; Morrison SL; Chintalacharuvu KR
    J Immunol Methods; 2009 Jan; 340(1):1-10. PubMed ID: 18848836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human immunoglobulin (Ig)A1 and IgA2 anti-D used for detection of IgA deficiency and anti-IgA.
    Nielsen LK; Dziegiel MH
    Transfusion; 2008 Sep; 48(9):1892-7. PubMed ID: 18513252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D.
    Kumpel BM
    Vox Sang; 1997; 72(1):45-51. PubMed ID: 9031501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
    Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
    Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
    Preston MJ; Gerçeker AA; Reff ME; Pier GB
    Infect Immun; 1998 Sep; 66(9):4137-42. PubMed ID: 9712759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity.
    Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M
    Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
    Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and specification of noncomplement binding anti-HLA alloantibodies.
    Arnold ML; Zacher T; Dechant M; Kalden JR; Doxiadis II; Spriewald BM
    Hum Immunol; 2004 Nov; 65(11):1288-96. PubMed ID: 15556679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
    Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity.
    Zhao J; Yan Y; Cui Z; Yang R; Zhao MH
    Hum Immunol; 2009 Jun; 70(6):425-9. PubMed ID: 19364515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis.
    Kumpel BM; Leader KA; Merry AH; Hadley AG; Poole GD; Blancher A; Goossens D; Hughes-Jones NC; Bradley BA
    Eur J Immunol; 1989 Dec; 19(12):2283-8. PubMed ID: 2481589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shedding of Fc receptor from mononuclear cells and their ability of binding IgG1 and IgG3 anti-Rh/D antibodies.
    Maślanka K; Erdei A
    Arch Immunol Ther Exp (Warsz); 1988; 36(1):15-22. PubMed ID: 3148299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.